Aurinia Pharmaceuticals (AUPH) Other Non-Current Assets (2016 - 2026)
Aurinia Pharmaceuticals posted quarterly Other Non-Current Assets of $93000.0 for Q1 2026, down 88.7% year-on-year from $823000.0 in Q1 2025, and little changed on a QoQ basis from $93000.0 in Q4 2025.
Aurinia Pharmaceuticals (AUPH) has 11 years of Other Non-Current Assets data on file, last reported at $93000.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets fell 88.7% year-over-year to $93000.0; the trailing twelve-month figure through Mar 2026 stood at $93000.0 (down 88.7% YoY), and the FY2025 full-year result was $93000.0, down 88.7% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $93000.0, roughly flat from $93000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $13.3 million in Q4 2022 and bottomed at $93000.0 in Q2 2025.
- The 5-year median for Other Non-Current Assets is $868000.0 (2024), against an average of $3.6 million.
- The widest annual swing landed in 2022, when Other Non-Current Assets surged 4346.33%; it then tumbled 94.09% in 2023.
- A 5-year view of Other Non-Current Assets shows it stood at $13.3 million in 2022, then slumped by 88.63% to $1.5 million in 2023, then plunged by 45.75% to $823000.0 in 2024, then slumped by 88.7% to $93000.0 in 2025, then changed by 0.0% to $93000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $93000.0 (Q1 2026), $93000.0 (Q4 2025), and $93000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Aurinia Pharmaceuticals | 2.03 Bn | 1.65 Bn | 71.20 Mn | 93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | 93,000.00 |
| Sep 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | 823,000.00 |
| Dec 31, 2024 | 823,000.00 |
| Sep 30, 2024 | 868,000.00 |
| Jun 30, 2024 | 867,000.00 |
| Mar 31, 2024 | 1.50 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.52 Mn |
| Jun 30, 2023 | 1.52 Mn |
| Mar 31, 2023 | 700,000.00 |
| Dec 31, 2022 | 13.34 Mn |
| Sep 30, 2022 | 13.05 Mn |
| Jun 30, 2022 | 12.36 Mn |
| Mar 31, 2022 | 11.84 Mn |
| Dec 31, 2021 | 300,000.00 |
| Sep 30, 2021 | 11.84 Mn |
| Jun 30, 2021 | 11.86 Mn |
| Mar 31, 2021 | 11.86 Mn |
| Dec 31, 2020 | 247,000.00 |
| Sep 30, 2020 | 209,000.00 |
| Jun 30, 2020 | 209,000.00 |
| Mar 31, 2020 | 209,000.00 |
| Dec 31, 2019 | 209,000.00 |
| Sep 30, 2019 | 615,000.00 |
| Jun 30, 2019 | 358,000.00 |
| Mar 31, 2019 | 358,000.00 |
| Dec 31, 2018 | 399,000.00 |
| Sep 30, 2018 | 697,000.00 |
| Jun 30, 2018 | 702,000.00 |
| Mar 31, 2018 | 708,000.00 |
| Dec 31, 2017 | 479,000.00 |
| Sep 30, 2017 | 448,000.00 |
| Jun 30, 2017 | 448,000.00 |
| Dec 31, 2016 | 29,000.00 |